Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biosense Webster, Inc.
This study is to measure the "real-world" acute procedural outcomes (procedural efficiency, acute safety, and effectiveness at one year) associated with use of the NAVISTAR® THERMOCOOL® SF Catheter in a clinical setting in subjects with drug refractory, recurrent symptomatic paroxysmal atrial fibrillation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation
Age 18 years or older
Patients must be able and willing to provide written informed consent to participate in the study
You may not be if
Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
Previous ablation for atrial fibrillation
Episodes of atrial fibrillation that last longer than 30 days and are terminated via cardioversion
Uncontrolled heart failure, or NYHA Class III or IV heart failure
Documented intra-atrial thrombus or other abnormality on pre-ablation echocardiogram
Contraindication to anticoagulation
Stroke, cardiac surgery, unstable angina, myocardial infarction or percutaneous coronary intervention within the past 3 months
Awaiting cardiac transplantation
Heart disease in which corrective surgery is anticipated within 6 months
Enrollment in investigational drug, biologic or device study
Subjects unwilling to comply with protocol or follow-up requirements